Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT04432207 2026-03-25

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Phase 1 Terminated

24 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04911166 2026-03-24

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Phase 1 Terminated

13 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07322341 2026-03-13

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

24 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Completed

131 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

18 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

498 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02525757 2026-02-04

MPDL3280A With Chemoradiation for Lung Cancer

52 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06267001 2026-02-03

SKYSCRAPER-15

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04294810 2026-01-30

SKYSCRAPER-01

620 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Phase 1/2 Recruiting

25 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2 Terminated

3 enrolled 12 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03782207 2026-01-08

IMreal

Active not recruiting

2,756 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT04691817 2026-01-07

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Phase 1/2 Recruiting

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04471428 2025-12-22

CONTACT-01

366 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05171777 2025-12-11

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

179 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

438 enrolled 40 charts 1 FDA

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT06332755 2025-11-24

LB-LR1109

Phase 1 Recruiting

76 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT07153445 2025-11-19

ATHENEA

Phase 2 Recruiting

97 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04549428 2025-11-18

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

Phase 2 Terminated

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05781308 2025-11-18

ADAPTABLE

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02599454 2025-10-27

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

20 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05334329 2025-10-15

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

6 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

51 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled